Goldman analyst James Kelly cut his rating from “buy†to “neutral†and price target from $26 to $22 for Pfizer Inc. (PFE)...
Continue Reading Big Pharma Stock Pfizer Downgraded, Could Mark Bottom
Continue Reading Big Pharma Stock Pfizer Downgraded, Could Mark Bottom
